Entropy Neurodynamics Limited (ENP) - Total Liabilities
Based on the latest financial reports, Entropy Neurodynamics Limited (ENP) has total liabilities worth AU$1.02 Million AUD (≈ $722.06K USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Entropy Neurodynamics Limited long-term investment intensity to see how much of total assets are deployed in long-term investments.
Entropy Neurodynamics Limited - Total Liabilities Trend (2018–2026)
This chart illustrates how Entropy Neurodynamics Limited's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see ENP asset base.
Entropy Neurodynamics Limited Competitors by Total Liabilities
The table below lists competitors of Entropy Neurodynamics Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cherrybro co.Ltd
KQ:066360
|
Korea | ₩188.30 Billion |
|
Hyundai Industrial Co. Ltd
KQ:170030
|
Korea | ₩82.12 Billion |
|
Indonesia Energy
NYSE MKT:INDO
|
USA | $3.28 Million |
|
Digihost Technology Inc
V:DGHI
|
Canada | CA$12.34 Million |
|
Viewbix Inc. Common Stock
NASDAQ:VBIX
|
USA | $5.77 Million |
|
Wisekey International Holding AG
NASDAQ:WKEY
|
USA | $53.44 Million |
|
Elton International Trading Company S.A
AT:ELTON
|
Greece | €51.37 Million |
|
Analabs Resources Bhd
KLSE:7083
|
Malaysia | RM305.62 Million |
Liability Composition Analysis (2018–2026)
This chart breaks down Entropy Neurodynamics Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is Entropy Neurodynamics Limited's balance sheet to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.94 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Entropy Neurodynamics Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Entropy Neurodynamics Limited (2018–2026)
The table below shows the annual total liabilities of Entropy Neurodynamics Limited from 2018 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-06-30 | AU$1.02 Million ≈ $722.06K |
+45.96% |
| 2025-06-30 | AU$699.17K ≈ $494.71K |
-61.85% |
| 2024-06-30 | AU$1.83 Million ≈ $1.30 Million |
+4.47% |
| 2023-06-30 | AU$1.75 Million ≈ $1.24 Million |
-63.50% |
| 2022-06-30 | AU$4.81 Million ≈ $3.40 Million |
+85.57% |
| 2021-06-30 | AU$2.59 Million ≈ $1.83 Million |
+69.81% |
| 2020-06-30 | AU$1.53 Million ≈ $1.08 Million |
+442.75% |
| 2019-06-30 | AU$281.00K ≈ $198.83K |
-10.94% |
| 2018-06-30 | AU$315.53K ≈ $223.26K |
-- |
About Entropy Neurodynamics Limited
Entropy Neurodynamics Limited, a clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs in Australia, Canada, Switzerland, and the United States. The company's lead program candidate is TRP-8803, a formulation of IV-infused psilocin that completed Phase 2 … Read more